Evidence map›Paper›PMID 34060379›Full record

ReviewClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination.

Bulent Kantarcioglu, Omer Iqbal, Jeanine M Walenga, Bruce Lewis, Joseph Lewis, Charles A Carter, Meharvan Singh, Fabio Lievano, Alfonso Tafur, Eduardo Ramacciotti and 3 more

Open access · goldAbstract readReview
In one paragraph

Review in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 2 pooled it
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Consequences and implications of the coronavirus disease (COVID-19) on pregnancy and newborns: A comprehensive systematic review and meta-analysis.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2022
    Pooled it
  2. Guideline
  3. Review
  4. Article
  5. [Research on immunological function of platelet receptor FcγRⅡA].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Article
  6. Article
  7. Article
  8. Observational
  9. SARS-CoV-2 in brief: from virus to prevention.Osong public health and research perspectives · 2022
    Article
  10. Review
  11. Article
  12. Adamalysins in COVID-19 - Potential mechanisms behind exacerbating the disease.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022
    Review
  13. Stroke Associated with COVID-19 Vaccines.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2022
    Review
  14. Article
  15. Article
  16. Review
  17. COVID-19 mRNA Vaccine-induced Pneumonitis.Internal medicine (Tokyo, Japan) · 2022
    Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Bulent KantarciogluDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.ORCID https://orcid.org/0000-0003-3060-721X
Omer IqbalDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Jeanine M WalengaDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.ORCID https://orcid.org/0000-0002-1418-7369
Bruce LewisDepartment of Medicine, Cardiology, 2456Loyola University Medical Center, Maywood, IL, USA.
Joseph LewisDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Charles A CarterDepartment of Clinical Research, 2078Campbell University College of Pharmacy and Health Sciences, Campbell University, Buies Creek, NC, USA.ORCID https://orcid.org/0000-0002-4302-0402
Meharvan SinghDepartment of Cellular and Molecular Physiology, 2456Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
Fabio LievanoDepartment of Medical Safety Evaluation, 359181AbbVie Inc., North Chicago, IL, USA.
Alfonso TafurSection of Interventional Cardiology and Vascular Medicine, 3271NorthShore University Health System, Evanston, IL, USA.
Eduardo RamacciottiHemostasis & Thrombosis Research Laboratories at 2456Loyola University Medical Center, Maywood, IL, USA.ORCID https://orcid.org/0000-0002-5735-1333
Grigoris T Gerotziafas5-Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Thrombosis Center, Service D'Hématologie Biologique Hôpital Tenon, Paris, France.ORCID https://orcid.org/0000-0003-2316-6348
Walter JeskeDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.
Jawed FareedDepartment of Pathology and Laboratory Medicine, Cardiovascular Research Institute, 2456Loyola University Chicago, Health Sciences Division, Maywood, IL, USA.ORCID https://orcid.org/0000-0003-3465-2499
Loyola University Chicago · USLoyola University Medical Center · USAbbVie (United States) · USCampbell University · USNorthShore University HealthSystem · USSorbonne Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Today the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global health problem. After more than a year with the pandemic, although our knowledge has progressed on COVID-19, there are still many unknowns in virological, pathophysiological and immunological aspects. It is obvious that the most efficient solution to end this pandemic are safe and efficient vaccines. This manuscript summarizes the pathophysiological and thrombotic features of COVID-19 and the safety and efficacy of currently approved COVID-19 vaccines with an aim to clarify the recent concerns of thromboembolic events after COVID-19 vaccination. The influx of newer information is rapid, requiring periodic updates and objective assessment of the data on the pathogenesis of COVID-19 variants and the safety and efficacy of currently available vaccines.

Indexed as

SARS-CoV-2Ad26COVS1AutoantibodiesBNT162 VaccineChAdOx1 nCoV-19Clinical Trials as TopicCOVID-19COVID-19 VaccinesDisseminated Intravascular CoagulationDrug ApprovalFemaleGenetic VectorsGlycosaminoglycansHumansMaleModels, CardiovascularAd26COVS1AutoantibodiesBNT162 VaccineChAdOx1 nCoV-19COVID-19 VaccinesGlycosaminoglycansmRNA VaccinesNVX-CoV2373 adjuvated lipid nanoparticlePF4 protein, humanPlatelet Factor 4Vaccines, InactivatedVaccines, SyntheticCOVID-19heparin induced thrombocytopeniasafety and efficacySARS-CoV-2thrombocytopeniathrombosis

Identifiers

PMID34060379
PMCPMC8173993
OpenAlexW3165405162

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.